HK1049832A1 - 雪花胺的新衍生物和类似物 - Google Patents

雪花胺的新衍生物和类似物 Download PDF

Info

Publication number
HK1049832A1
HK1049832A1 HK03101873.7A HK03101873A HK1049832A1 HK 1049832 A1 HK1049832 A1 HK 1049832A1 HK 03101873 A HK03101873 A HK 03101873A HK 1049832 A1 HK1049832 A1 HK 1049832A1
Authority
HK
Hong Kong
Prior art keywords
nmr
substituted
alkyl
cdcl
compound
Prior art date
Application number
HK03101873.7A
Other languages
English (en)
Chinese (zh)
Inventor
U‧乔迪斯
U‧喬迪斯
J‧福罗里克
M‧特鲁
J‧福羅裡克
M‧赫恩夏尔
L‧斯佐尔纳
M‧特魯
B‧卡尔兹
S‧维尔兹格
M‧赫恩夏爾
L‧斯佐爾納
B‧卡爾茲
S‧維爾茲格
Original Assignee
萨诺化学药物股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 萨诺化学药物股份公司 filed Critical 萨诺化学药物股份公司
Publication of HK1049832A1 publication Critical patent/HK1049832A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
HK03101873.7A 2000-03-31 2001-03-22 雪花胺的新衍生物和类似物 HK1049832A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AT5462000 2000-03-31
ATA546/2000 2000-03-31
AT2382001 2001-02-15
ATA238/2001 2001-02-15
PCT/AT2001/000082 WO2001074820A1 (de) 2000-03-31 2001-03-22 Neue derivate und analoga von galanthamin

Publications (1)

Publication Number Publication Date
HK1049832A1 true HK1049832A1 (zh) 2003-05-30

Family

ID=25608130

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101873.7A HK1049832A1 (zh) 2000-03-31 2001-03-22 雪花胺的新衍生物和类似物

Country Status (26)

Country Link
US (2) US7166588B2 (enExample)
EP (1) EP1181294B1 (enExample)
JP (1) JP2003529602A (enExample)
CN (1) CN1380883A (enExample)
AT (1) ATE263171T1 (enExample)
AU (1) AU785385B2 (enExample)
BG (1) BG65134B1 (enExample)
BR (1) BR0105563A (enExample)
CA (1) CA2368966A1 (enExample)
CZ (1) CZ300160B6 (enExample)
DE (1) DE50101827D1 (enExample)
DK (1) DK1181294T3 (enExample)
ES (1) ES2215885T3 (enExample)
HK (1) HK1049832A1 (enExample)
HU (1) HUP0202233A3 (enExample)
IS (1) IS2287B (enExample)
MX (1) MXPA01012275A (enExample)
NO (1) NO326458B1 (enExample)
NZ (1) NZ516302A (enExample)
PL (1) PL202463B1 (enExample)
PT (1) PT1181294E (enExample)
RU (1) RU2241001C2 (enExample)
SI (1) SI1181294T1 (enExample)
SK (1) SK285909B6 (enExample)
TR (1) TR200400857T4 (enExample)
WO (1) WO2001074820A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
WO2003080623A1 (de) * 2002-03-25 2003-10-02 Sanochemia Pharmazeutika Aktiengesellschaft Verfahren zur herstellung von norgalanthamin, ihren isomeren, salzen und hydraten
AT414125B (de) * 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
US7877350B2 (en) * 2005-06-27 2011-01-25 Ab Initio Technology Llc Managing metadata for graph-based computations
ATE473219T1 (de) * 2005-09-22 2010-07-15 Galantos Pharma Gmbh Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2008022365A2 (de) * 2006-08-24 2008-02-28 Sanochemia Ltd. Mittel zum beeinflussen der wirkungen von organophosphorverbindungen und verwendung von galanthamin, dessen derivaten und analoga zum herstellen solcher mittel
EP2137192B8 (en) 2008-04-14 2014-06-11 Neurodyn Life Sciences Inc. Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
BG110141A (en) * 2008-05-23 2009-12-31 "Софарма" Ад GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE
WO2011159759A1 (en) 2010-06-15 2011-12-22 Ab Initio Technology Llc Dynamically loading graph-based computations
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
US10108521B2 (en) * 2012-11-16 2018-10-23 Ab Initio Technology Llc Dynamic component performance monitoring
SG11201604525TA (en) 2013-12-05 2016-07-28 Ab Initio Technology Llc Managing interfaces for dataflow graphs composed of sub-graphs
CN106687918B (zh) 2014-09-02 2020-08-28 起元科技有限公司 编译基于图的程序规范
SG11201701662XA (en) 2014-09-02 2017-04-27 Ab Initio Technology Llc Visually specifying subsets of components in graph-based programs through user interactions
US10657134B2 (en) 2015-08-05 2020-05-19 Ab Initio Technology Llc Selecting queries for execution on a stream of real-time data
US12006301B1 (en) 2021-05-13 2024-06-11 Florida A&M University And synthesis of dual 5-HT1A and 5-HT7 receptor ligands
CN116082352A (zh) * 2023-02-16 2023-05-09 西南交通大学 一种加兰他敏衍生物及其制备方法和用途
CN118908968B (zh) * 2024-10-09 2025-03-04 威胜生物医药(苏州)股份有限公司 一种加兰他敏中间体衍生物及其催化氧化制备方法
CN119528922B (zh) * 2024-11-22 2025-12-09 泰安汉威集团有限公司 一种氢溴酸加兰他敏关键杂质-氢溴酸表加兰他敏的手性合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947445A (en) 1974-05-09 1976-03-30 Stanford Research Institute Diazabicyclooctanes and diazabicycloheptanes
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE3856594D1 (de) 1987-05-04 2008-11-27 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
US4954502A (en) 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
US5336675A (en) 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US5428159A (en) 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
AT401058B (de) 1994-10-21 1996-06-25 Waldheim Pharmazeutika Gmbh Verfahren zum herstellen von derivaten des 4a,5, 9,10,11,12,-hexahydro-6h-benzofuro(3a,-3,2-ef) (2)benzazepins
EP0787115B1 (de) * 1994-10-21 2000-01-05 Sanochemia Pharmazeutika AG VERFAHREN ZUM HERSTELLEN VON DERIVATEN DES 4a,5,9,10,11,12,-HEXAHYDRO-6H-BENZOFURO[3a,3,2-ef][2]BENZAZEPINS
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
GB9519268D0 (en) 1995-09-21 1995-11-22 Chiroscience Ltd Preparation of alkaloids
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
AU1430099A (en) * 1998-12-01 2000-06-19 Sanochemia Pharmazeutika Aktiengesellschaft Use of galanthamine and galanthamine derivatives in the case of acute functionalbrain damage
AT414125B (de) 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln

Also Published As

Publication number Publication date
HK1045990A1 (en) 2002-12-20
IS2287B (is) 2007-10-15
SK17022001A3 (sk) 2003-02-04
EP1181294A1 (de) 2002-02-27
AU785385B2 (en) 2007-03-29
PL202463B1 (pl) 2009-06-30
CN1380883A (zh) 2002-11-20
BG65134B1 (bg) 2007-03-30
PL352638A1 (en) 2003-09-08
SK285909B6 (sk) 2007-10-04
MXPA01012275A (es) 2003-06-24
NO20015857L (no) 2002-01-29
DK1181294T3 (da) 2004-08-02
PT1181294E (pt) 2004-07-30
US7166588B2 (en) 2007-01-23
CZ20014178A3 (cs) 2002-11-13
NZ516302A (en) 2004-02-27
US20030199493A1 (en) 2003-10-23
CZ300160B6 (cs) 2009-02-25
DE50101827D1 (de) 2004-05-06
WO2001074820A1 (de) 2001-10-11
RU2241001C2 (ru) 2004-11-27
NO326458B1 (no) 2008-12-08
HUP0202233A3 (en) 2004-12-28
CA2368966A1 (en) 2001-10-11
BG106155A (en) 2002-08-30
BR0105563A (pt) 2002-04-02
ES2215885T3 (es) 2004-10-16
AU4208501A (en) 2001-10-15
JP2003529602A (ja) 2003-10-07
HUP0202233A2 (hu) 2002-11-28
NO20015857D0 (no) 2001-11-30
IS6174A (is) 2001-11-23
TR200400857T4 (tr) 2004-06-21
US20070027138A1 (en) 2007-02-01
SI1181294T1 (en) 2004-08-31
ATE263171T1 (de) 2004-04-15
EP1181294B1 (de) 2004-03-31

Similar Documents

Publication Publication Date Title
CN1380883A (zh) 雪花胺的新衍生物和类似物
CN1069624C (zh) 4a,5,9,10,11,12－六氢－6H－苯并呋喃并[3a,3,2－ef][2]苯并吖庚因衍生物的制备方法
US10618901B2 (en) LRRK2 inhibitors for the treatment of Parkinson's disease
CN1154650C (zh) 三唑并[4,5-d]嘧啶类化合物、其制备、用途和含有其的药物组合物
CN103201260B (zh) 药物衍生物
CN1662506A (zh) 治疗中枢和周围神经系统疾病的方法和组合物及其有用的新化合物
CN1675218A (zh) 新的三环螺哌啶或螺吡咯烷
US20230331720A1 (en) Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
CN1371374A (zh) 取代的杂环稠合γ－咔啉
CN1063430C (zh) 乙醇胺衍生物
CN101039672A (zh) 化合物
CN113754654A (zh) 咪唑并吡啶类化合物及其用途
US20250236629A1 (en) Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses
CN1816551A (zh) 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
CN1918160A (zh) 用作趋化因子受体活性调节剂的新颖三环螺环衍生物
CN1286683A (zh) 四氢苯并吲哚衍生物
CN112218871A (zh) 噻吩并[2,3-c]哒嗪-4(1H)-酮类衍生物及其应用
CN1074214A (zh) 异喹啉磺酰胺衍生物的制备方法
EP4724426A1 (en) Statin derivatives and methods of using the same
KR100768245B1 (ko) 신규한 갈란타민 유도체 및 유사체
CN1223656A (zh) 螺－哌啶衍生物及其作为治疗剂的用途
HK1081872A (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
HK1096384A (en) Novel derivatives and analogues of galanthamin
HK1088900A1 (zh) 吡咯并哒嗪衍生物
HK1088900B (en) Pyrrolopyridazine derivatives